Patent Number: 6,169,107

Title: Indoloylguanidine derivatives

Abstract: Novel indoloylguanidine derivatives shown by formula (1), wherein R.sub.1 represents one or more, the same or different substituent(s) which is selected from the group consisting of a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a halogen atom, nitro group, an acyl group, carboxyl group, an alkoxycarbonyl group, an aromatic group, and a group shown by formula: --OR.sub.3, --NR.sub.6 R.sub.7, --SO.sub.2 NR.sub.6 R.sub.7 or --S(O).sub.n R.sub.40 ; and R.sub.2 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, hydroxy group, an alkoxy group or a group shown by formula: --CH.sub.2 R.sub.20 ; and which inhibit the Na.sup.+ /H.sup.+ exchanger activity and are useful for the treatment and prevention of a disease caused by increased Na.sup.+ /H.sup.+ exchanger activity, such as hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, disorders associated with ischemia or ischemic reperfusion, cerebro-ischemic disorders; or diseases caused by excessive cell proliferation.

Inventors: Kitano; Masahumi (Takatsuki, JP), Nakano; Kazuhiro (Osaka, JP), Yagi; Hideki (Osaka, JP), Ohashi; Naohito (Takatsuki, JP), Kojima; Atsuyuki (Takarazuka, JP), Noguchi; Tsuyoshi (Toyonaka, JP), Miyagishi; Akira (Takatsuki, JP)

Assignee: Sumitomo Pharmaceutical Co., Ltd.

International Classification: C07D 209/42 (20060101); C07D 209/08 (20060101); C07D 209/00 (20060101); A61K 031/404 (); C07D 209/14 ()

Expiration Date: 01/02/2018